These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34038996)

  • 21. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
    Wi YM; Kim SH; Peck KR
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
    Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
    Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
    J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.
    Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA
    Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.
    Enayatrad M; Mahdavi S; Aliyari R; Sahab-Negah S; Nili S; Fereidouni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Sharifi H; Emamian MH
    BMC Infect Dis; 2023 Mar; 23(1):150. PubMed ID: 36899326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
    Oyebanji OA; Wilson B; Keresztesy D; Carias L; Wilk D; Payne M; Aung H; Denis KS; Lam EC; Rowley CF; Berry SD; Cameron CM; Cameron MJ; Schmader KE; Balazs AB; King CL; Canaday DH; Gravenstein S
    Aging Clin Exp Res; 2021 Nov; 33(11):3151-3160. PubMed ID: 34652783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
    Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
    Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial.
    Janssen C; Cachanado M; Ninove L; Lachatre M; Michon J; Epaulard O; Maakaroun-Vermesse Z; Chidiac C; Laviolle B; Aumaitre H; Assaf A; Lacombe K; Schmidt-Mutter C; Botelho-Nevers E; Briere M; Boisson T; Loubet P; Bienvenu B; Bouchaud O; Touati A; Pereira C; Rousseau A; Berard L; Montil M; de Lamballerie X; Simon T; Launay O;
    EClinicalMedicine; 2022 Jun; 48():101444. PubMed ID: 35582124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
    Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
    Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
    Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
    PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination.
    Lim SY; Kim JY; Park S; Kwon JS; Park JY; Cha HH; Suh MH; Lee HJ; Lim JS; Bae S; Jung J; Lee N; Kim K; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Dec; 21(6):e41. PubMed ID: 35036028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
    Terpos E; Karalis V; Ntanasis-Stathopoulos I; Evangelakou Z; Gavriatopoulou M; Manola MS; Malandrakis P; Gianniou DD; Kastritis E; Trougakos IP; Dimopoulos MA
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.